Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : La Jolla Diagnostics, Inc.(OTC BB: LAJD) -- Ignore unavailable to you. Want to Upgrade?

To: Lazarus who wrote (128)	12/15/1999 11:29:00 PM
From: GARY P GROBBEL	Respond to of 168

Laz...they have had a couple of releases out in past few weeks...filings are pretty informative...gpg

To: Lazarus who wrote (128)	12/16/1999 10:00:00 AM
From: Madeleine Harrison	Read Replies (1) \| Respond to of 168

Yes. (COMTEX) B: La Jolla Diagnostics TB Test To Enter Southern African Market LA JOLLA, Calif., Dec 16, 1999 (BW HealthWire) -- La Jolla Diagnostics Inc. (OTCBB:LAJD), announced today that Alton Health International will market their DiagnosTech Rapid TB test in South Africa and surrounding states. DiagnosTech Inc. a subsidiary of La Jolla Diagnostics, manufactures and markets the Rapid TB test as a means of quickly, inexpensively, and accurately determining the presence of active TB. The company believes this unique test has widespread application in screening, treatment and prevention. This is especially true in areas such as parts of Southern Africa where TB is endemic. TB represents a major threat to health throughout the world. Up to one-third of the world's population is infected with the organism responsible for TB, of which approximately 10% are expected to develop active disease and thus require treatment. The World Health Organization estimates that approximately 1 billion TB tests will be performed worldwide in the year 2000. Alton Health is a prominent South African firm, which recently obtained South African government approval for both the home and clinical version of DiagnosTech's Rapid HIV I & II. The tests were recently tested by the National Institute of Virology in Johannesburg, South Africa, a World Health Organization Collaborating Center, and were found to be 100% sensitive and 100% specific. As such, both tests are approved for sale. The DiagnosTech HIV home test is the only home/self test approved in South Africa. The test was recently introduced throughout the country by leading pharmacies. Now that the Rapid HIV Test introduction is underway, Alton Health is ready to turn its attention to the Rapid TB Test. La Jolla Diagnostics is an emerging company engaged in the development and marketing of state-of-the-art diagnostic tests (including the proprietary test for active tuberculosis), health care products and dietary supplements. The healthcare and dietary supplement products are formulated using proprietary technology. Forward-looking statements in this release are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risk and uncertainties. Copyright (C) 1999 Business Wire. All rights reserved. Distributed via COMTEX. -0- CONTACT: La Jolla Diagnostics Inc. Investor Relations, 800/454-6790, Fax 858/454-7851 lajd.com lajd96@aol.com